Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

US FDA gives green light for use of AstraZeneca's Voydeya

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH). PNH is a condition under which some patients' immune systems destroy a larger proportion of red blood cells than they should, whilst EVH is the condition in which red blood cells outside of blood vessels were destroyed.

Voydeya could now be used as an add-on therapy to ravulizumab or eculizumab to treat EVH in adults with PNH.

The drug was a first-in-class, oral, Factor D inhibitor meant to address the needs of the roughly 10-20% of patients with PNH experiencing "clinically significant" EVH when they were being treated with a C5 inhibitor.

Share this article

Related Sharecast Articles

Kefi shares pop on official launch of Tulu Kapi
(Sharecast News) - Kefi Gold and Copper officially launched the Tulu Kapi Gold Mines (TKGM) project in Ethiopia on Monday.
Sajid Javid reportedly in talks to join Shein ahead of London IPO
(Sharecast News) - Singapore-based fast fashion retailer Shein has reportedly approached the former chancellor Sajid Javid about joining the company ahead of its rumoured listing on the London Stock Exchange.
Bradda Head reaches settlement over fraudulent payment
(Sharecast News) - North America-focussed lithium developer Bradda Head announced on Monday that it has reached a settlement agreement over the fraudulent payment initially reported on 29 March 2022.
SDI Group set to end year in line with forecasts
(Sharecast News) - Scientific digital imaging, sensing and control technology company SDI Group said in a trading update on Monday that, pending its final accounts and audit, it expected to report revenue of £65.9m for the year, in line with current market expectations, but slightly down from £67.6m in 2023.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.